many throughout the two Thanks, last the March. sales sales mid-March, It elective Axonics prior Dan. COVID-XX-related peaked In dropped And from momentum off medical first of device procedures. in postponement quarter, accelerated the companies, heard weeks to for quarter. as other considerably you've in of our
were During per we approximately million new averaging in the $X week quarter, sales orders.
sales days XX the were April, first of of the very first days light. or calendar In April, particularly new days
However, during last the month days, of we in the May. week orders new have last a and few rescheduled being particularly number procedures seen of
on how will recover scope, duration depend the exactly things and and When of the quickly the and the pandemic intensity of recovery. shape
are than on March external are to there control. for understands, our and which factors back slower – related online of in Europe earlier accounts went of be instance, everyone be much out appears which appears a to less dark much in for COVID-XX U.S. our X% As the coming business than
slow QX of implants. X, New along XX. calendar reports with widely. external that little on region. York, do Jersey, very Northeast Our Massachusetts, that have Irvine XX% say Rocky this rescheduled. team to up procedures or the not we reopen, see as to full had May of opening would parts The on trials of UC New to activity California of cases include we activity doing Mountain a of number Texas U.S. be There's in Florida, just We compared approximately will been originally permanent the field field begin until although June. Midwest May modest in looks location – and These Louisiana elective our varies notify the the as also
of physicians be In revenue as we be their patients due negatively to the and elective manufacturing lack online. modest in any back addition, margin quarter reduced the impacted are case, we given we significantly Despite to support signs, encouraging to reopen gross expect to overhead ready the procedures procedures. continue And second these to expect in come number absorption. scheduled facilities and of
in given shape approximately procedures of With that the patients surgery most Medicare all and are age our in one of that quickly. urologists to that profitable procedures centers good ambulatory XX% believe and we approximately XX% and is are our for of of Sacral said, urogynecologists, Neuromodulation is Axonics recover
and Moreover, XXXX. are positioned that know hospitals. And generating for to customers June, to bloom in recovery second is and well half practices in of their the full the assuming during XXXX grow to is begin we continue Axonics income into anxious our
received in November since from quarter and launch to back the the So commercial first feedback had our fact of which validate talking we our in results, XXXX. about physicians
the seminars that with enthusiasm series seminar or our analysts of series at was held we in from market QX U.S. – sell-side many XXXX, into As the held met physicians. – we saw great series or entry firsthand the seminar
agreement physicians successful dare approximately program on complete a time Axonics pleased return Needless with seminar series from their of that us. the say, attended our was of XXX In purchased significant investment an to that fact, we're and I already report to to products with very waiting, the that for have institutions two-thirds say a this more provided impatiently capital.
Sacral enthusiastic meaning due of more our patient current easy be the stimulation our in easy tell that staff and of are benefits product, with recommending is patients perceived constant their satisfaction report Implanting us and by Neuromodulation of therapy because high level to our that a physicians remote. product Their patients. they to to charging use members to and highlighting confident
required to is staff nursing There the at the little by reprogramming office. no
for physicians prior consideration. gives as Sacral some resort last Neuromodulation implanters this being used only Sacral to this In therapy. that and is was an more So Neuromodulation important a Axonics, physician recommend to confidence
are are before. However, us projected and of level ever to of more Neuromodulation patients on patients, the Sacral that to confidence of attractiveness physicians their therapy embodiment physicians by our saying based yes than their telling the being
reinforce years the expansion extent commitment to our by and poised for patient market large So meaningful Axonics' ahead, to driven increasing awareness. the Sacral that Neuromodulation confidence innovation a is this quarter's results in
overactive fully We the suffering Sacral future and incontinence. Neuromodulation are fecal for preferred to patients expect and bullish bladder about the third-line from therapy become
that information interesting. people additional will some So trust find I
quarter, account XXXX hospitals all That over during first centers about practice Axonics you ambulatory the and we've top represents for great centers customer Sacral third the XXX the surgery of XX% system. front. SNM. on patients about implanted those may of and with So made in if that United Neuromodulation And one implantations. progress centers States acquisition the the contracting And
well been signed have regional centers U.S. ambulatory Further, agreements as XXX in surgery large urology with national since facility over XXXX. and IDNs both groups our and as launch
in IDNs largest in group, United this the March, are included three the Now in States. executed of
agreements that Now we the XX are XX in March -- we've and continued XXXX. progress currently execute during And due COVID-XX, expect or some agreements by approximately there currently have fully And summer another will in that while up April. may delays wrapped that agreements be to agreements be process. are remaining to we in
surprised that not been trialed time with than our to-date is In System XX% expecting been clinical of running nearly physicians in are InterStim External with This device. the market data implants our all been And have of literature. U.S. pleasantly the XX% meaningfully higher addition, have InterStim historically over to launch, of permanent about associated Trial replacing while in our at is with we Axonics. with were showing of what IPG patients we participate our has a reported XX% implanted to replacement XX% the that
this moving FDA between with interval the with extended in completed our why IPG that and recharging an by reason of already is we forward to new get is main with the IPG an the a So, on lieu advancements decided approved we incremental InterStim -- round as our continue a as non-rechargeable to the we on work Sacral well number implanted existing diligently lead. R&D out to system And are front, Neuromodulation line. device the to of or compatible
the to we the development proud have in for trust regulatory Axonics. progress and commercial We're in continue in initiatives. quarter's of results. we're this product their grateful on So, very patients strong And physicians excellent placed to make and execution, addition closing,
surveys As United in Dan the can in will conducted the and three physician to many investors, market we independent years. the times and believe past double in and by and over Sacral said by Neuromodulation as next the global I States expand size analysts have particular meaningfully in supported five numerous
confident are we we work prospects said, that future with Axonics to So fulfill the every bullish and diligently to about continue our and day of vision.
to time happy to I, I'm pass at -- So, the up. to going happy it this to questions answer and to operator answer and it Neil Dan we're are open
